A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of famitinib
combined with HS-10296 in subjects with advanced EGFR-mutant NSCLC.